

# Euromed Pharmaceuticals Ltd

Annual Report and Unaudited Financial Statements  
for the Year Ended 31 March 2018

Kajaine Limited  
Kajaine House  
57-67 High Street  
Edware  
HA8 7DD

# Euromed Pharmaceuticals Ltd

## Contents

Company Information	<u>1</u>
Balance Sheet	<u>2</u>
Notes to the Financial Statements	<u>3 to 5</u>

# **Euromed Pharmaceuticals Ltd**

## **Company Information**

**Director** Mr B.S. Dhaliwal

**Registered office** Unit 4, Progress Business Centre  
Whittle Parkway  
Slough  
SL1 6DQ

**Accountants** Kajaine Limited  
Kajaine House  
57-67 High Street  
Edgware  
HA8 7DD

**Euromed Pharmaceuticals Ltd**  
**(Registration number: 07495412)**  
**Balance Sheet as at 31 March 2018**

	Note	2018 £	2017 £
<b>Current assets</b>			
Debtors	<u>3</u>	172,147	52,306
Cash at bank and in hand		17,835	475
		189,982	52,781
<b>Creditors: Amounts falling due within one year</b>	<u>4</u>	(213,637)	(77,789)
<b>Net liabilities</b>		(23,655)	(25,008)
<b>Capital and reserves</b>			
Called up share capital	<u>5</u>	1	1
Profit and loss account		(23,656)	(25,009)
<b>Total equity</b>		(23,655)	(25,008)

For the financial year ending 31 March 2018 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the director on 20 December 2018

.....  
 Mr B.S. Dhaliwal  
 Director

The notes on pages 3 to 5 form an integral part of these financial statements.  
 Page 2

# **Euromed Pharmaceuticals Ltd**

## **Notes to the Financial Statements for the Year Ended 31 March 2018**

### **1 General information**

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:

Unit 4, Progress Business Centre  
Whittle Parkway  
Slough  
SL1 6DQ  
United Kingdom

These financial statements were authorised for issue by the director on 20 December 2018.

### **2 Accounting policies**

#### **Summary of significant accounting policies and key accounting estimates**

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

#### **Statement of compliance**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

#### **Basis of preparation**

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

#### **Going concern**

The financial statements have been prepared on a going concern basis, as in the opinion of the director he shall continue to financially support the company in the foreseeable future to meet the liabilities as they fall due.

#### **Revenue recognition**

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company's activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:

The amount of revenue can be reliably measured;  
it is probable that future economic benefits will flow to the entity;  
and specific criteria have been met for each of the company's activities.

#### **Tax**

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

# Euromed Pharmaceuticals Ltd

## Notes to the Financial Statements for the Year Ended 31 March 2018

### Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

### Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

### Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

### 3 Debtors

	2018 £	2017 £
Trade debtors	172,044	50,265
Other debtors	103	-
Corporation tax recoverable	-	2,041
	<hr/>	<hr/>
Total current trade and other debtors	<u>172,147</u>	<u>52,306</u>

## Euromed Pharmaceuticals Ltd

### Notes to the Financial Statements for the Year Ended 31 March 2018

#### 4 Creditors

##### Creditors: amounts falling due within one year

	Note	2018 £	2017 £
<b>Due within one year</b>			
Trade creditors		165,165	7,196
Taxation and social security		-	5,350
Other creditors		47,663	37,663
Accrued expenses		800	27,580
Corporation tax payable		9	-
		<u>213,637</u>	<u>77,789</u>

#### 5 Share capital

##### Allotted, called up and fully paid shares

	2018		2017	
	No.	£	No.	£
Ordinary shares of £1 each	1	1	1	1

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.